Adverse events47

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 47

Type	Event	Organ system	Group	Affected	At risk	Events
other	Bruising (in absence of Grade 3 or 4 thrombocytopenia)	Skin and subcutaneous tissue disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	2	38	2
other	Fracture	Musculoskeletal and connective tissue disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	2	38	2
other	Lymphocele	Blood and lymphatic system disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	2	38	2
other	Mood alteration - Anxiety	Nervous system disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	2	38	2
other	Neuropathy: sensory	Nervous system disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	2	38	2
other	Ocular/Visual - vision impaired	Eye disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	2	38	2
other	Ophthalmoplegia/diplopia (double vision)	Eye disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	2	38	2
other	Pain - Back	General disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	2	38	3
other	Pain - Extremity-limb	General disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	2	38	2
other	Pain - Joint	General disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	2	38	2
other	Sweating (diaphoresis)	General disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	2	38	2
other	Taste alteration (dysgeusia)	Gastrointestinal disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	2	38	2
other	Dizziness	Nervous system disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	3	38	4
other	Flushing	Skin and subcutaneous tissue disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	3	38	3
other	Hair loss/alopecia (scalp or body)	Skin and subcutaneous tissue disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	3	38	3
other	Heartburn/dyspepsia	Gastrointestinal disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	3	38	5
other	Injection site reaction/extravasation changes	Skin and subcutaneous tissue disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	3	38	3
other	Insomnia	General disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	3	38	4
other	Potassium, serum-high (hyperkalemia)	Metabolism and nutrition disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	3	38	3
other	Potassium, serum-low (hypokalemia)	Metabolism and nutrition disorders	Arm I: Dacarbazine + Recombinant Interferon Alfa-2b	3	38	4

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01100528/events

API reference For AI assistants

Adverse events47

Sources 3

Read this list from software.